Frazier Management’s Cidara Therapeutics CDTX Stock Holding History

Frazier Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-65,613	Closed	-$3.74M	–	36
2020 Q3	$3.74M	Hold	65,613	–	–	0.34%	22
2020 Q2	$4.84M	Hold	65,613	–	–	0.43%	20
2020 Q1	$3.25M	Hold	65,613	–	–	0.37%	18
2019 Q4	$5.04M	Hold	65,613	–	–	0.85%	16
2019 Q3	$2.62M	Hold	65,613	–	–	0.82%	16
2019 Q2	$2.21M	Hold	65,613	–	–	0.57%	17
2019 Q1	$3.48M	Hold	65,613	–	–	0.84%	17
2018 Q4	$3.08M	Hold	65,613	–	–	0.8%	16
2018 Q3	$5.77M	Hold	65,613	–	–	1.06%	15
2018 Q2	$6.82M	Hold	65,613	–	–	1.41%	12
2018 Q1	$5.25M	Hold	65,613	–	–	0.87%	10
2017 Q4	$8.92M	Hold	65,613	–	–	1.45%	9
2017 Q3	$10.6M	Hold	65,613	–	–	3.79%	8
2017 Q2	$9.84M	Hold	65,613	–	–	5.04%	6
2017 Q1	$10.2M	Hold	65,613	–	–	5.47%	6
2016 Q4	$13.6M	Hold	65,613	–	–	17.18%	3
2016 Q3	$15M	Hold	65,613	–	–	7.37%	5
2016 Q2	$13.5M	Hold	65,613	–	–	10.79%	5
2016 Q1	$16.7M	Hold	65,613	–	–	10.26%	5
2015 Q4	$22.5M	Buy	+65,613	New	+$19.7M	9.42%	6

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Frazier Management's CDTX Position: Q4 2020 in Review

Frazier Management sold out of Cidara Therapeutics (CDTX) in Q4 2020, closing a stake of 65,613 shares — an estimated $3.74M sold.

Frazier Management first reported a position in CDTX in Q4 2015 and held it in 20 quarters. The position peaked at $22.5M in Q4 2015. 63 funds tracked by Wall St. Rank hold CDTX as of Q4 2020.

Frazier Management reported no remaining Cidara Therapeutics position as of Q4 2020 after selling out during the quarter.
Frazier Management sold 65,613 Cidara Therapeutics shares in Q4 2020, an estimated $3.74M.
Frazier Management first reported a position in Cidara Therapeutics in Q4 2015 and held it in 20 quarters.
Frazier Management's Cidara Therapeutics position peaked at $22.5M in Q4 2015.
63 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2020.

Based on Frazier Management's 13F filing for Q4 2020, filed 11 Feb 2021.